- Home
- DSP vs STTK Comparison
DSP vs STTK Comparison
Compare DSP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- STTK
- Stock Information
- Founded
- DSP 1999
- STTK 2016
- Country
- DSP United States
- STTK United States
- Employees
- DSP N/A
- STTK N/A
- Industry
- DSP EDP Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- STTK Health Care
- Exchange
- DSP Nasdaq
- STTK Nasdaq
- Market Cap
- DSP 291.3M
- STTK 56.8M
- IPO Year
- DSP 2021
- STTK 2020
- Fundamental
- Price
- DSP $17.53
- STTK $1.12
- Analyst Decision
- DSP Strong Buy
- STTK Hold
- Analyst Count
- DSP 7
- STTK 3
- Target Price
- DSP $17.71
- STTK $2.00
- AVG Volume (30 Days)
- DSP 198.1K
- STTK 182.2K
- Earning Date
- DSP 03-03-2025
- STTK 02-27-2025
- Dividend Yield
- DSP N/A
- STTK N/A
- EPS Growth
- DSP N/A
- STTK N/A
- EPS
- DSP 0.08
- STTK N/A
- Revenue
- DSP $263,587,000.00
- STTK $6,435,000.00
- Revenue This Year
- DSP $28.26
- STTK $313.04
- Revenue Next Year
- DSP $12.19
- STTK N/A
- P/E Ratio
- DSP $230.51
- STTK N/A
- Revenue Growth
- DSP 23.73
- STTK 382.75
- 52 Week Low
- DSP $6.50
- STTK $0.94
- 52 Week High
- DSP $21.74
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- DSP 39.72
- STTK 43.75
- Support Level
- DSP $16.78
- STTK $1.13
- Resistance Level
- DSP $19.95
- STTK $1.39
- Average True Range (ATR)
- DSP 0.88
- STTK 0.11
- MACD
- DSP -0.40
- STTK 0.00
- Stochastic Oscillator
- DSP 19.93
- STTK 18.18
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.